Headquartered in Malvern, PA Fiscal year ends December NASDAQ: OCGN ocugen.com
Ocugen, Inc. is a clinical-stage biotechnology company developing gene therapies for blindness diseases using a modifier gene therapy platform. The platform is gene-agnostic: rather than targeting a single mutation, it aims to restore balance across multiple gene networks.
Its three late-stage programs are:
- **OCU400** for retinitis pigmentosa, covering 100+ RP-causing genes. It is in the 140-patient Phase 3 liMeliGhT trial, with enrollment complete, and holds a provisional approval for an early access program in The Bahamas.
- **OCU410ST** for Stargardt disease, in the pivotal Phase 2/3 GARDian3 trial.
- **OCU410** for geographic atrophy secondary to dry age-related macular degeneration, in the global 240-subject Phase 3 ArMaDa3 trial.
The company currently earns collaborative arrangement revenue. It is pursuing regional out-licensing of OCU400, with Kwangdong Pharmaceutical in South Korea and Roots Pharmaceutical in MENA, and plans to manufacture commercial supply. It has established a European affiliate in Amsterdam to prepare for EU marketing authorization submissions and potential commercialization. Updated
Oppenheimer initiated coverage of Ocugen (NASDAQ:OCGN) with an Outperform rating and a $10 price target on Wednesday, positioning the clinical-stage gene therapy company as an emerging leader in blinding ocular disorders. The…
Joel South Wednesday’s top analyst upgrades and downgrades included Baidu, BJ’s Wholesale Club, CrowdStrike, Ocugen, Palo Alto Networks, PayPal, Playtika, Schlumberger, Workday and Zoom Video Communications.
Stocks were indicated down before the opening bell Monday. A couple of meme stocks were bucking the trend, and one acquisition target was soaring.
Meme stocks traded well-mixed at midday Thursday. The morning's most surprising turn came from a stock that missed estimates and gave lower guidance but still traded higher.
U.S. stock markets were having an off-day Tuesday, and the meme stocks were as well -- with the exception of a look-alike to GameStop's position one year ago.
Trading wa light again Thursday, but one meme stock was making some real noise.
AMC stock got a big bump on Friday thanks to a new Spider-Man movie, but Monday's downturn was taking back a small piece of the big gain.
Markets were waiting with bated breath the FOMC announcement. In the meantime, there are always new Elon Musk tweets to ponder.
Several beaten-down meme stocks were getting some love as investors decided that Tuesday was a good day for taking on risk.
Reduced concern for the impact of the Omicron variant of the coronavirus lifted stocks higher on Monday. The effect appeared to be continuing in Tuesday's premarket trading.
Despite Friday's sharp drop in equity prices, there were a couple of winners. Premarket trading indicated a higher open, with crude oil up well over 5%.
Friday's shortened trading session was dominated by the news of a new coronavirus variant and its impact on investors.
An FDA directive has hammered a coronavirus vaccine maker Friday morning as a new variant of the infection is discovered in South Africa.
A strong October jobs report lit a fire under traders in Friday's premarket. One of Thursday's big movers added a bit more Friday morning and another was dropping after reporting earnings.
Why does a coronavirus vaccine maker's stock drop more than 20% after the vaccine is approved for use? It happened Wednesday.
Ocugen, Inc. is a clinical-stage biotechnology company developing gene therapies for blindness diseases using a modifier gene therapy platform. The platform is gene-agnostic: rather than targeting a single mutation, it aims to restore balance across multiple gene networks.
The Wall Street consensus 12-month price target for OCGN is $12.17.
